Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477374 | 0.88 | MAPK8 (0.44) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31290659 | 0.87 | MAPK8 (0.43) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30722219 | 0.87 | MAPK8 (0.43) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Formic Acid SCHEMBL29924695 | 0.83 | MAPK8 (0.41) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Formic Acid SCHEMBL30537910 | 0.83 | MAPK8 (0.41) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Formic Acid SCHEMBL29924830 | 0.83 | MAPK8 (0.41) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL29925165 | 0.80 | MAPK8 (0.39) | MAPK8SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| SCHEMBL3637625 | 0.78 | ALDH1A1 (0.51) | SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL11208928 | 0.78 | TNKS2 (0.37) | SMN1; SMN2KDM4EALDH1A1HSD17B10DYRK1A | |
| SCHEMBL4658884 | 0.74 | KDM4E (0.44) | MAPK8SMN1; SMN2KDM4EALDH1A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211296-B2 | Therapeutic compounds for blocking DNA synthesis of POX viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130338117-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-12-19 | — | — | US | disclosed |
| US-8524719-B2 | Therapeutic compounds for blocking DNA synthesis of pox viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-20 | — | — | US | disclosed |
| US-8278342-B2 | Therapeutic compounds for blocking DNA synthesis of pox viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| WO-2009008906-A2 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | MAPK8 2499/4885SMN1; SMN2 4176/4885KDM4E 970/4885 |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | MAPK8 2499/4885SMN1; SMN2 4176/4885KDM4E 970/4885 |
| US-20130338117-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | MAPK8 2499/4885SMN1; SMN2 4176/4885KDM4E 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.